Data Curation and Entry in DIDB – April Summary

In April, we added 92 citations in DIDB, including 44 in vitro (with 22 articles published in Apr. 2022) and 48 in vivo articles (with 36 articles published in Apr. 2022).

Four recently approved NDAs/BLAs were also added with the following 3 NDAs: utetium Lu-177 vipivotide tetraxetan (PLUVICTO), mitapivat (PYRUKYND), pacritinib (VONJO), and the following BLA: nivolumab and relatlimab (OPDUALAG).

You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.

As always, feel free to contact us if you have any questions or comments.

DDI Marker Studies Knowledgebase updated

The DDI Marker Studies Knowledgebase (replacing the previous combined and individual lists of CYP/P-gp substrates and perpetrators) has been updated and is available in the DIDB Resource Center.

Note, that we have initiated the gradual expansion of the Knowledgebase with more transporter data beyond P-gp. Thus, in this version, you will find data for BCRP and OATP1B1/1B3. More transporter data will be added throughout the year.

In addition to substrates, inhibitors and inducers of CYPs and transporters, the Knowledgebase provides useful information on the compounds therapeutic class, clinical recommended dosage, pharmacokinetics (e.g. dose proportionality accumulation ratio, time to steady-state), QT prolongation, and NTI characteristics

As always, feel free to contact us if you have any questions or comments.

Data Curation and Entry in DIDB – March Summary

In March, we added 104 citations in DIDB, including 37 in vitro (with 11 articles published in Mar. 2022) and 67 in vivo articles (with 19 articles published in Mar. 2022).

Four recently approved NDAs/BLAs were also added with the following 1 NDA: daridorexant (QUVIVIQ), and the following 3 BLAs: faricimab (VABYSMO), sutimlimab (ENJAYMO), tebentafusp (KIMMTRAK).

You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.

As always, feel free to contact us if you have any questions or comments.

Data Curation and Entry in DIDB – February Summary

In February, we added 126 citations in DIDB, including 43 in vitro (with 21 articles published in Feb. 2022) and 83 in vivo articles (with 30 articles published in Feb. 2022).

One NDA approved in Jan.2022 was also added: abrocitinib (CIBINQO).

You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.

As always, feel free to contact us if you have any questions or comments.

UW Pharmacy’s Drug Interaction Database, built to promote medication safety, wins national innovation award

2022 marks 20 years of DIDB licensing and the selection by the ASCPT of Dr. René Levy and Dr. Isabelle Ragueneau-Majlessi to receive the 2022 Gary Neil Prize for Innovation in Drug Development.

Read the story here: https://www.washington.edu/news/2022/01/13/uw-pharmacys-drug-interaction-database-built-to-promote-medication-safety-wins-national-innovation-award/

Lists of Sensitive Substrates, Inhibitors and Inducers updated

The lists of sensitive substrates, inhibitors, and inducers, including the file combining all lists, have been updated and are available in the DIDB Resource Center.

A total of 18 drug interactions, involving 13 drugs, were added to the October version or were updated. Nine of these drugs were cancer treatments, including 7 kinase inhibitors, being identified as sensitive substrates or perpetrators of CYP enzymes or the P-gp transporter.

As always, feel free to contact us if you have any questions or comments.

Continuing Education Course on Drug Interactions

Senior team members, Dr Jingjing Yu and Dr Cathy Yeung, are instructing a CE course on Principles & Mechanisms of Pharmacokinetic Drug-Drug Interactions for Recently Approved Drugs which provides pharmaceutical scientists and clinical pharmacists with an in-depth understanding of the mechanisms of drug interactions.

This 5-session course was prepared in collaboration with University of Wisconsin-Madison.

To learn more and register, visit here.

FDA Draft Guidance Gastric pH-Dependent Drug Interactions with Acid-Reducing Agents

The draft guidance newly released by FDA on “Evaluation go Gastric pH-Dependent Drug Interactions with Acid-Reducing Agents: Study Design, Data Analysis, and Clinical Implications” is now available in DIDB Resource Center. Please note that you must be signed in to access.

This draft guidance describes FDA’s recommendations regarding: (1) when clinical DDI studies with acid-reducing agents are needed; (2) the design of clinical DDI studies; (3) how to interpret study results; and (4) communicating findings in product labeling.

DIDB contains absorption-based drug interaction data. The study results are presented based on the underlying mechanism. For example, there are about 450 entries on pH-dependent drugs interactions in DIDB curated from literature and NDA reviews with detailed information about PK assessment results, study design, population, formulation, dosing, and safety results